中泰证券股份有限公司 关于上海美农生物科技股份有限公司 保荐机构根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司股东减持股份管理暂行办法》《深圳证券交易所上市公司自律监管指引第 18 号——股东及董事、高级管理人员减持股份》《上市公司监管指引第 4 号— —上市公司及其相关方承诺》以及其他有关法规、指引等，对注册制下创业板 上市公司股份变动相关规定、关联方的确认和关联交易的认定、募集资金存放 和使用关注要点以及上市公司相关被监管/处分案例等进行了培训。 三、培训结论 本次培训得到了美农生物的积极配合，全体参与培训人员进行了认真学习， 加强了关于注册制下创业板上市公司股份变动及规范运作等要求的认识，进一 步理解了其对自身信息披露等方面应承担的责任和义务，本次培训达到了预期 目标，取得了良好效果。 2025 年度持续督导培训情况报告 中泰证券股份有限公司（以下简称"中泰证券"、"保荐机构"）作为上海美 农生物科技股份有限公司（以下简称"美农生物"、"公司"）首次公开发行股票 并在创业板上市的保荐机构和持续督导机构，根据《深圳证券交易所上市公司 自律监管指引第 13 号——保荐业务》的要求，对美农生 ...

Group 1 - The core viewpoint of the articles highlights the strong performance of Meino Biological in the first half of 2025, with a revenue of 236 million yuan, a year-on-year increase of 13.69%, and a net profit attributable to shareholders of 23.527 million yuan, up 17.68% [1] - The company has maintained a robust growth in its international business, achieving over 20% growth in overseas revenue, amounting to 90.5632 million yuan in the first half of the year, with significant contributions from markets in Vietnam, Russia, Brazil, and several other countries [2] - Meino Biological aims to evolve into a global resource integration platform for the livestock industry, leveraging its international business network to export quality additives and introduce advanced products to China, enhancing the efficiency of domestic feed and breeding enterprises [3] Group 2 - The "Annual Production of 100,000 Tons of Corn Protein Refining Project" is progressing rapidly and is expected to begin trial production within the year, which will help alleviate the domestic shortage of protein resources in feed [4] - The new corn protein products, including corn concentrated protein and corn enzymatic protein, will significantly improve the nutritional value and digestibility of corn protein, meeting the high protein demands of poultry and aquaculture [4] - The company is actively applying for patents related to the production processes of its new products, indicating a commitment to innovation and product development [4]

Core Insights - Shanghai Meino Biological Technology Co., Ltd. reported a revenue of 236 million yuan for the first half of 2025, representing a year-on-year growth of 13.69% [1] - The company's net profit attributable to shareholders reached 23.53 million yuan, up 17.68% year-on-year, while the net profit after deducting non-recurring items was 21.84 million yuan, reflecting a growth of 27.46% [1] Market Strategy - The company adheres to a market strategy of "deepening domestic operations and breaking into international markets" and a product strategy of "diversified seeds and products, full-process nutrition" [1] - Meino Biological aims to become a global leader in animal nutrition technology, emphasizing its mission of providing better solutions for animals and humans [1] International Business Performance - The company's international business continues to perform well, with a dual approach of "going out" to develop new markets and "digging in" to deepen existing market value [1] - The revenue from international business has approached 40% of the company's total operating income, maintaining a growth rate of over 20% [1] Product Development - The company focuses on industry demands for "quality improvement and efficiency enhancement" and "green safety," continuously developing efficient, safe, and environmentally friendly feed additives and hydrolyzed protein feed raw materials [2] - The revenue from the main feed additive and hydrolyzed protein feed raw material business has seen varying degrees of growth compared to the same period last year, with the intestinal health product segment experiencing over 60% year-on-year growth, significantly contributing to the company's overall performance [2]

Core Viewpoint - The company announced the approval of multiple proposals, including the "2025 Semi-Annual Report" and its summary, during the 14th meeting of the fifth board of directors [2] Group 1 - The company held its 14th meeting of the fifth board of directors on August 27 [2] - The board approved the proposal regarding the "2025 Semi-Annual Report" and its summary [2]

Core Insights - Meino Bio (301156.SZ) reported a revenue of 236 million yuan for the first half of 2025, representing a year-on-year growth of 13.69% [1] - The company achieved a net profit attributable to shareholders of 23.53 million yuan, up 17.68% year-on-year, and a net profit excluding non-recurring items of 21.84 million yuan, which is a 27.46% increase [1] - Operating cash flow increased by 70.09% year-on-year, indicating an ongoing optimization of the financial structure [1] Company Performance - International market performance was strong, with overseas revenue reaching 90.56 million yuan, growing over 20% year-on-year, and sales covering more than 40 countries across Asia, Europe, and Africa [1] - The company participated in international exhibitions and hosted over 100 overseas clients, showcasing significant global expansion efforts [1] Research and Development - The company made breakthroughs in R&D, adding two new patents related to cleaning wastewater recovery systems and improving thermal efficiency in coating machines [1] - Chengdu Meiyide, a subsidiary, received recognition as one of the "Top 100 Brands in China's Aquaculture Industry" [1] Production and Digital Transformation - The annual production project of 100,000 tons of corn protein processing in Shandong is set to alleviate the domestic shortage of feed protein materials and is expected to begin trial production within the year [1] - The company is advancing its digital transformation, having implemented intelligent manufacturing MES systems in its Shanghai and Suzhou plants to enhance production control [1] Product Strategy - The product structure has been optimized, with gut health products like "Meile Zinc" becoming significant growth drivers [2] - The development of non-grain protein raw materials in the enzymatic protein feed business aligns with national food security strategies by reducing reliance on soybean meal and fish meal [2] Industry Context - The overall production in China's livestock industry remains stable, with a 2.8% year-on-year increase in the production of pork, beef, mutton, and poultry in the first half of 2025, providing stable demand for the feed additive industry [2] - Meino Bio's product strategy of "dividing by species and products, full-process nutrition" is being implemented across multiple sectors, including pigs, ruminants, and poultry, which is expected to further enhance performance as the corn protein processing project comes online [2]

Group 1 - The company achieved operating revenue of 236 million yuan in the first half of 2025, representing a year-on-year growth of 13.69% [1] - The net profit attributable to shareholders of the listed company was 23.527 million yuan, an increase of 17.68% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 21.841 million yuan, reflecting a year-on-year growth of 27.46% [1] - The basic earnings per share were 0.1667 yuan [1]

| 非经营性资金占用 | 资金占用方名称 | 占用方与上 市公司的关 | 上市公司核 算的会计科 | 2025 年期初占用 | 2025 年半年度占 用累计发生金额 | 2025 年半 年度占用资 金的利息 | 2025 年半年度偿 还累计发生金额 | 2025 年半年度期 末占用资金余额 | 占用形成原 因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 联关系 | 目 | 资金余额 | (不含利息) | (如有) | | | | | | 控股股东、实际控制人及 其附属企业 | 无 | | | | | | | - | | | | 小计 | — | — | — | - | - | - | - | - | | | | 前控股股东、实际控制人 及其附属企业 | 无 | | | | | | | - | | | | 小计 | — | — | — | - | - | - | - | - | | | | 其他关联方及其附属企 业 | 无 | | | | | | | - | | | | 小计 | — | — ...

证券代码：301156 证券简称：美农生物 公告编号：2025-052 上海美农生物科技股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》及相关格式指引，上海美农生物科技股 份有限公司（以下简称"公司"）董事会对 2025 年半年度募集资金存放与使用 情况进行专项说明如下： 一、募集资金基本情况 （一）募集资金金额及资金到账情况 经中国证券监督管理委员会《关于同意上海美农生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2022〕790 号）同意注册，公司首次公 开发行股份数量 20,000,000 股，发行价格为 23.48 元/股，本次募集资金合计 46,960.00 万元，扣除发行费用（不含税）后募集资金净额 40,503.31 万元。已 由主承销商中泰证券股份有限公司（以下简称"中泰证券"）于 2022 年 6 月 14 日汇入公司募集资金专户。容诚会计师事务所（特殊普通 ...

Group 1 - The report indicates that the sponsor, Zhongtai Securities, has effectively reviewed the company's information disclosure documents with no instances of delayed reviews [1] - The company has established and effectively executed regulations to prevent related parties from occupying company resources and to manage fundraising [1] - The sponsor conducted six inquiries into the usage of the company's fundraising special account as of mid-year [1] Group 2 - There were no significant issues identified by the sponsor regarding the company's operations or financial management [1] - The company has fulfilled its commitments, with no reasons for non-compliance reported [1] - The sponsor verified that the conditions affecting the performance of major contracts have not changed significantly, indicating no major risks of contract non-fulfillment [2]

上海美农生物科技股份有限公司 2025 年半年度报告全文 上海美农生物科技股份有限公司 2025 年半年度报告 2025-051 2025 年 8 月 1 上海美农生物科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人洪伟、主管会计工作负责人周茜及会计机构负责人(会计主管 人员)周茜声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告涉及的未来发展战略与规划、经营计划与目标等前瞻性陈述，不 构成公司对投资者的实质承诺。投资者及相关人士均应对此保持足够的风险 认识，并应理解计划、预测与承诺之间的差异。 公司在发展过程中，存在市场竞争、原材料价格波动、养殖业阶段性波 动、境外市场环境变化等风险因素，敬请广大投资者注意投资风险，详细内 容见本报告"第三节 管理层讨论与分析"之"十、公司面临的风险和应对措 施"部分。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 ...